Tags : Vir Biotechnology

Regulatory

GSK and Vir Receive the US FDA’s EUA for Sotrovimab

Shots: The US FDA has granted EUA for sotrovimab for mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progression to severe COVID-19 including hospitalization for >24hrs. or death The EUA is based on an interim analysis from the P-III COMET-ICE trial that demonstrated an 85% reduction in hospitalization or death. […]Read More

Clinical Trials COVID-19

Eli Lilly Collaborates with GSK and VIR to Evaluate Bamlanivimab

Shots: Lilly has expanded its ongoing BLAZE-4 trial to assess the administration of bamlanivimab (700mg) with VIR-7831 (500mg) for symptomatic COVID-19 in the outpatient setting. These are two neutralizing Abs that bind to different epitopes of the SARS-CoV-2 spike protein The companies reported the first patient has been dosed in the expanded study Bamlanivimab is […]Read More

Weekly Snapshot

PharmaShots Weekly Snapshot (Oct 5-9, 2020)

Takeda Signs ~$1B Pact with Arrowhead for ARO-AAT Targeting Alpha-1 Antitrypsin-Associated Liver Disease    Published: Oct 9, 2020 | Tags: Alpha-1 Antitrypsin-Associated Liver Disease, Arrowhead, Collaborates, Commercialize. ARO-AAT, Develop, Takeda, with Lilly and Incyte’s Olumiant (baricitinib) Reports Additional Data Demonstrating Reduction in COVID-19 Recovery Time  Published: Oct 9, 2020 | Tags: COVID-19, Demonstrate, Incyte, Lilly, […]Read More

COVID-19 Pharma

Samsung Biologics Signs an Agreement with Vir Biotechnology to Develop

Shots: The total deal value is $362M and under this agreement, Samsung is expected to commence its manufacturing till Oct in Plant 3, with expected commercialization in early 2021. Additionally, the companies will continue to negotiate terms in agreement with expected finalization till Jul 31, 2020 The agreement follows the Vir’s manufacturing collaboration with WuXi […]Read More

Insights+

Insights+: COVID-19 Healthcare News Updates

Our planet is facing a major pandemic outbreak due to COVID-19 and health agencies are taking every measure to stop it. The outbreak of the respiratory disease was first detected in Wuhan City, Hubei Province, China in Dec 2019. PharmaShots is keeping a track of all of the important updates in the Lifesciences sector, where […]Read More